Partow Kebriaei, MD, stem cell transplant physician, The University of Texas MD Anderson Cancer Center, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

Patients with ALL must be minimal residual disease (MRD) negative in order to qualify for transplant, Kebriaei explains. As a patient goes beyond first remission, the likelihood of achieving MRD negativity decreases. Generally, if a patient is in remission and morphologic is adequate, then they are fit to undergo transplant, says Kebriaei.

Now, patients are being taken in for transplant after their third, fourth, or fifth line of therapy. In the past, they would not be expected to obtain response; however, now these patients are obtaining response and, therefore, can receive a transplant, concludes Kebriaei.

Videos

Partow Kebriaei, MD, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

Dr. Kebriaei on Eligibility for Stem Cell Transplant in ALL

Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses the SIERRA clinical trial, in which patients over the age of 55 with acute myeloid leukemia (AML) are receiving treatment with a radiolabeled anti-CD45 antibody known as Iomab-B or conventional therapy as a preconditioning regimen before allogeneic hematopoietic cell transplantation.

The targeted administration of radiation helps to treat older patients with AML, as it is a less intense therapy, notes Kabriaei. This reduced intensity is especially important for older patients, who tend to have less tolerance for toxicities. Iomab-B offers a novel therapy for this population of patients, she adds. 

View more from the 2017 BMT Tandem Meetings

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

Partow Kebriaei, MD

Articles

Dr. Kebriaei on Eligibility for Stem Cell Transplant in ALL

Dr. Kebriaei on the Iomab-B Clinical Trial